ClinicalTrials.Veeva

Menu

An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)

Roche logo

Roche

Status

Terminated

Conditions

Breast Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT01277133
ML25191

Details and patient eligibility

About

This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.

Enrollment

83 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients, >/=18 years of age
  • Previously untreated metastatic breast cancer
  • Scheduled to start 1st line chemotherapeutic treatment
  • ECOG performance status 0-1

Exclusion criteria

  • Any conditions included in contraindication list for Avastin
  • Prior chemotherapy for metastatic breast cancer
  • Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic malignancy completed <6 months prior to treatment start

Trial design

83 participants in 1 patient group

Cohort

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems